Flumetasone
From Wikipedia, the free encyclopedia
|
Flumetasone
|
|
| Systematic (IUPAC) name | |
| (6S,8S,9S,10S,11S,13S,14S,16R,17R)-6,9-difluoro- 11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16- trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a] phenanthren-3-one |
|
| Identifiers | |
| CAS number | |
| ATC code | D07 D07XB01 |
| PubChem | |
| Chemical data | |
| Formula | C22H28F2O5 |
| Mol. mass | 410.452 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | Hepatic, CYP3A4-mediated |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | Topical |
Flumetasone (usually as the pivalic acid ester flumetasone pivalate, trade name Locacorten or Locorten) is a corticosteroid for topical use. It is available in combination with clioquinol, under the trade name Locacorten-Vioform (in some countries Locorten-Vioform), for the treatment of otitis externa and otomycosis.

